19. Epigenomics – Impact for Drug Safety Sciences

  1. Saura C. Sahu
  1. Harri Lempiäinen,
  2. Raphaëlle Luisier,
  3. Arne Müller,
  4. Philippe Marc,
  5. David Heard,
  6. Federico Bolognani,
  7. Pierre Moulin,
  8. Philippe Couttet,
  9. Olivier Grenet,
  10. Jennifer Marlowe,
  11. Jonathan Moggs and
  12. Rémi Terranova

Published Online: 8 AUG 2012

DOI: 10.1002/9781118349045.ch19

Toxicology and Epigenetics

Toxicology and Epigenetics

How to Cite

Lempiäinen, H., Luisier, R., Müller, A., Marc, P., Heard, D., Bolognani, F., Moulin, P., Couttet, P., Grenet, O., Marlowe, J., Moggs, J. and Terranova, R. (2012) Epigenomics – Impact for Drug Safety Sciences, in Toxicology and Epigenetics (ed S. C. Sahu), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781118349045.ch19

Editor Information

  1. Division of Toxicology, Center for Food Safety and Applied Nutrition, Food and Drug Administration, Laurel, Maryland, USA

Author Information

  1. Novartis Institutes for BioMedical Research, Preclinical Safety, Discovery and Investigative Safety, Basel, Switzerland

Publication History

  1. Published Online: 8 AUG 2012
  2. Published Print: 7 SEP 2012

ISBN Information

Print ISBN: 9781119976097

Online ISBN: 9781118349045



  • epigenomics and drug safety, and environmental, diet, stress, behavior;
  • dynamic epigenome and perturbations, MoA and novel therapeutics;
  • epigenetic regulation, immediate/long-term alterations;
  • epigenetic modifications, drug-induced toxicity biomarkers;
  • critical window, profiling methodologies and molecular perturbations;
  • epigenetic side-effects and common pharmaceuticals;
  • challenges, epigenomics into drug safety, relevant model systems;
  • NOAEL for pathology, risk management strategies;
  • promising DNA methylation biomarkers, in patient response to drugs


This chapter contains sections titled:

  • Introduction – the dynamic epigenome and perturbations in disease

  • Relevance of epigenetics for toxicology

  • Towards identifying epigenetic biomarkers of drug-induced toxicity

  • Challenges of integrating epigenetic analysis into toxicity testing

  • Practical considerations

  • Bioinformatics and modeling of epigenomic data

  • Case study: identification of early mechanism and biomarkers for non-genotoxic carcinogenesis (NGC)

  • Conclusions

  • Acknowledgments

  • References